SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH

Their core work

The Medical University of Silesia in Katowice is a Polish medical university contributing clinical expertise to large European health research consortia. Their work centers on cardiovascular disease treatment — including regenerative gene therapy for ischemic heart disease and sudden cardiac death prevention — and on type 1 diabetes research covering biomarker discovery, immunology, and clinical trial design. They serve as a clinical site and data contributor in multi-center trials, bringing patient cohorts and medical expertise from one of Poland's largest healthcare regions.

What they specialise in

How they've shifted over time

SUM's early H2020 work (2015–2017) focused on stem cell and regenerative approaches to heart disease (SCIENCE) alongside entering the large INNODIA diabetes consortium. From 2017 onward, their cardiovascular work shifted toward gene therapy (ReGenHeart) and clinical decision tools for sudden cardiac death prediction (PROFID), reflecting a move from experimental therapies toward implementable clinical solutions. Their diabetes work deepened with INNODIA HARVEST, expanding into microbiome and immunology dimensions.

SUM is moving from experimental regenerative therapies toward clinically deployable cardiac risk tools and deeper mechanistic diabetes research — a shift toward implementation and precision medicine.

How they like to work

SUM operates exclusively as a participant or third party — they have never coordinated an H2020 project, which is typical for a clinical site contributing patient cohorts and medical expertise to large consortia. With 99 unique partners across 20 countries, they are well-connected across European health research networks. Their repeat involvement in INNODIA/INNODIA HARVEST suggests they build lasting relationships within flagship research platforms.

SUM has collaborated with 99 unique partners across 20 countries, indicating broad European reach through large health consortia. Their network is driven by membership in major multi-center platforms like INNODIA rather than by bilateral partnerships.

What sets them apart

SUM brings clinical access to a large patient population in Poland's Upper Silesia region — one of the country's most densely populated and industrialized areas with correspondingly high cardiovascular disease burden. Their dual specialization in both cardiovascular regenerative medicine and type 1 diabetes gives them an unusual breadth for a clinical partner. For consortium builders, they offer a reliable Polish clinical site with proven experience in multi-center trial logistics across two major disease areas.

Highlights from their portfolio

• ReGenHeart
  Largest single grant (EUR 591,250) — clinical proof-of-principle for VEGF-D gene therapy in angina, representing the frontier of cardiac regenerative medicine.
• INNODIA / INNODIA HARVEST
  Eight-year continuous involvement (2015–2024) in Europe's premier type 1 diabetes research platform, demonstrating deep institutional commitment and trusted partner status.
• PROFID
  Most recent project (2020–2026) focused on personalized sudden cardiac death risk prediction — signals SUM's shift toward precision medicine and clinical decision support.